313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms
Manish R. Patel(Sarah Cannon), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Paul A. Moore(Zymeworks (Canada)), Francine Chen(MacroGenics (United States)), Cesar A. Santa‐Maria(Johns Hopkins University), Bartosz Chmielowski(UCLA Health), Janine Koucheki(MacroGenics (United States)), Shakeela Bahadur(The University of Texas MD Anderson Cancer Center), Sanjeev Kaul(AstraZeneca (United States)), George Blumenschein(The University of Texas MD Anderson Cancer Center), Jason J. Luke(University of Chicago), John Muth(MacroGenics (United States)), Patrick Kaminker(MacroGenics (United States)), Hedy L. Kindler(University of Chicago), Xiaoyu Zhang(Agilent Technologies (United States)), Erika Hamilton(Sarah Cannon), Jichao Sun(MacroGenics (United States)), Bradley Sumrow(MacroGenics (United States))
Cited by 6
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k